Skip to main content
Premium Trial:

Request an Annual Quote

Johannes Fruehauf, Jens Harborth, Greg Weaver

Premium
Cequent Pharmaceuticals said this week that it has named Johannes Fruehauf as its director of preclinical and clinical development.
 
Fruehauf was previously a senior research fellow at Harvard Medical School’s Beth Israel Deaconess Medical Center. He holds an MD from the University of Heidelberg and is a co-developer of Cequent’s core transkingdom RNAi technology.
 
Cequent also said that it has appointed Jens Harborth as its associated director of RNAi research.
 
Harborth was previously a senior scientist at Alnylam Pharmaceuticals. He holds a PhD in biochemistry from Georg-August University.
 

 
Talyst, a pharmacy automation firm, has named Greg Weaver as its CFO.
 

Weaver was previously senior vice president and CFO of Sirna Therapeutics, which was acquired by Merck earlier this year.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.